This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of the Zanubrutinib, Lenalidomide and Rituximab (ZR2) regimen in elderly treatment-naive patient with diffuse large B-cell lymphomas.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Induction therapy: The ZR2 regimen will be given from day 1 of each cycle of treatment. Each cycle will last for 21 days. Participants will receive a total of 6 cycles. Dosage: 1. Zanubrutinib, 160 mg bid, po, day 1-21; 2. Lenalidomide, 25 mg qd, po, day 2-11; 3. Rituximab, 375 mg/m2, ivgtt, day 1. Maintenance therapy: Patients who receive complete response or partial response after induction therapy will receive lenalidomide 25 mg qd po during 1-10 days in every 21 days, for a maximum of 2 years.
Shanghai Ruijin Hospital
Shanghai, Shanghai Municipality, China
Complete response rate
Time frame: At the end of Cycle 6 (each cycle is 21 days)
2-year progression-free survival
Time frame: 2 years after enrollment
2-year overall survival
Time frame: 2 years after enrollment
Incidence rate of adverse events
Time frame: From enrollment to study completion, a maximum of 3 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.